


## BEYOND LIPOPROTEIN A [Lp(a)]: A SMARTER WAY TO PREDICT AND PREVENT HEART DISEASE

Mason's innovative dual panel blood test provides a more comprehensive and precise evaluation of cardiovascular risk by measuring two key biomarkers: Lp(a) and Soluble Lectin-like Oxidized LDL Receptor-1 (sLOX-1).

- ☑ **Lp(a) Testing:** Identifies individuals at elevated risk for heart disease and stroke due to genetically determined high Lp(a) levels, which contribute to atherosclerosis and thrombosis.
- ☑ **Mass Spec. Analysis:** Measures vascular inflammation and oxidative stress, key indicators of endothelial dysfunction and plaque instability, providing deeper insights into cardiovascular health.

Unlike conventional Lp(a) tests that focus on cholesterol-related risk, this dual panel approach offers a more dynamic picture of vascular health, helping clinicians better identify high-risk patients, personalize treatment strategies, and improve early intervention efforts.

This test is designed for use in preventative cardiology, risk stratification, and clinical decision-making, empowering healthcare providers with a next-generation diagnostic tool for advancing cardiovascular care.



**For More Information contact:**  
**George Mason University, Office of Technology Transfer**  
**703-993-8933   ott@gmu.edu   <https://ott.gmu.edu/>**